Elicio Therapeutics Announces Publication of ELI-002 Updated AMPLIFY-201 Phase 1 Follow-up Data in Nature Medicine for Minimal Residual Disease (“MRD”) Positive, Adjuvant-Stage Patients - Candlesense
ELTX Clinical trials

Elicio Therapeutics Announces Publication of ELI-002 Updated AMPLIFY-201 Phase 1 Follow-up Data in Nature Medicine for Minimal Residual Disease (“MRD”) Positive, Adjuvant-Stage Patients

BOSTON, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the “Company”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced the publication of follow-up data from the Phase 1 AMPLIFY-201 study evaluating ELI-002 in the peer-reviewed scientific journal, Nature Medicine. The article, entitled, “Lymph-node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: Phase 1 AMPLIFY-201 trial final results,” highlights that with extended follow-up, more than two-thirds of participants (17 of 25) whose T cell responses exceeded the antitumor efficacy threshold experienced a significantly reduced risk for relapse or death.

Related Questions

How will the Phase 1 AMPLIFY‑201 data influence Elicio’s short‑term stock price? What does the reduced relapse/death risk in MRD‑positive adjuvant patients mean for the company’s valuation and future cash‑flow forecasts? How does ELI‑002’s efficacy and safety profile compare to competing KRAS‑targeted immunotherapies in pancreatic and colorectal cancer? Will the extended follow‑up results accelerate timelines for Phase 2/3 trials or trigger any regulatory fast‑track designations? What impact could this data have on potential partnership, licensing, or co‑development deals with larger pharma partners? Are there any safety signals or adverse events in the 25‑patient cohort that could affect risk perception among investors? How large is the addressable market for KRAS‑mutant pancreatic and colorectal cancers, and what market share could ELI‑002 realistically capture if later‑stage trials succeed? What are the expectations for enrollment and data readout from the next‑generation trial cohorts, and how might those milestones move the share price? Does the magnitude of relapse risk reduction outperform the current standard of care, and how might that influence pricing and reimbursement strategies? What are the potential upside and downside scenarios for the stock based on upcoming trial results and regulatory pathways?
Find similar articles on Candlesense globenewswire